Market Report Source

Overview

Introduction
The Dermatology Market Outlook to 2011 provides detailed analysis on 5 indications within the dermatology market, identifying high growth brands, future market leaders and key drug classes. The in-depth 6-year epidemiology and product sales forecasts in this report will enable you to plan effectively, evaluate changes in the competitive positions of leading companies and accurately benchmark your position.

Key findings of this new report

• The psoriasis market is forecast to post the most aggressive growth rates over the period to 2011, as Raptiva and Daivobet drive growth over the forecast period. Psoriasis treatments are forecast to expand sales at a CAGR of 12.5%, reaching sales of $1.9bn in 2011.
• With Roaccutane and Diane facing generic competition, the branded oral acne treatments market is set to decline over the forecast period. Forecast sales of the acne market are estimated at $2.7bn in 2011.
• The corticosteroid market was valued at $2,783m in 2005, 5.8% up on year previous sales of $2,630m. Triple combination anti-infective/corticosteroid therapies are driving growth, whilst widespread genericization is restraining growth of the class as a whole.

The 5 Major dermatological indications covered are:

*Acne

• Psoriasis
• Infectious diseases of the skin
• Dermatitis
• Rosacea

Your questions answered

• What will be the major growth indications in the dermatology area over the period 2006-11?
• How have recent major launches from companies such as Novartis, Astellas and Genentech performed?
• Which companies will become the key players in the dermatology area over the period 2006-11?
• Which products will be impacted by generic competitors over the period 2006-11?
• What will the competitive landscape in acne, psoriasis, dermatitis, rosacea, viral, bacterial and fungal dermatological infections look like in 2011?

This report will enable you to…

• Quantify patient potential, assess treatment trends and sales patterns with this report’s in-depth coverage of the 5 major dermatological indications, the US, Japanese and top EU 5 markets and the top 10 leading companies.
• Forecast sales of the major products in the dermatology area over the period 2006-11 in major dermatological indications, classes of treatments and by company.
• Evaluate how market share of leading companies, such as Novartis, GlaxoSmithKline and Schering Plough, will change over the next 6 years, and assess your competitive position within the market.
• Discover which indications have the greatest potential to provide franchise growth and understand the growth drivers of major classes of dermatological treatments including corticosteroids, anti-infectives, acne treatments and psoriasis treatments.

Table of Contents

The Dermatology Market Outlook to

Executive Summary

Patient potential

Global market analysis

Pipeline analysis

Competitive landscape

Chapter 1 Patient potential

Summary

Introduction

Acne

Overview

Diagnosis, treatment and management

Epidemiology

Forecast epidemiology

Psoriasis

Overview

Diagnosis, treatment and management

Epidemiology

Forecast epidemiology

Infectious diseases of the skin

Overview

Bacterial infections of the skin

Fungal infections of the skin

Viral infections of the skin

Diagnosis, treatment and management

Epidemiology

Viral skin infections

Fungal skin infections

Bacterial skin infections

Forecast epidemiology

Viral skin infections

Fungal skin infections

Bacterial skin infections

Dermatitis

Overview

Diagnosis, treatment and management

Epidemiology

Forecast epidemiology

Rosacea

Overview

Diagnosis, treatment and management

Epidemiology

Forecast epidemiology

Chapter 2 Global market analysis

Summary

Introduction

Market analysis by country

Licensing trends

Market analysis by drug class

Leading brands dynamics

Key events in the dermatology market

Continued approvals for biologic agents in the treatment of psoriasis

Black box warnings for Elidel and Protopic

Safety concerns over Roaccutane gain more traction

Acne treatments

Market analysis by drug class

Competitive dynamics of acne treatments

Leading acne treatment brands

Oral acne treatments market analysis

Market dynamics

Key brands analysis

Topical acne treatments market analysis

Market dynamics

Key brands analysis

Acne treatment sales forecasts to 2011

Psoriasis treatments

Market analysis by drug class

Competitive dynamics of psoriasis treatment classes

Leading brands of psoriasis treatments

Market dynamics

Key brands analysis

Psoriasis treatments sales forecasts to 2011

Corticosteroid treatments

Market analysis by drug class

Competitive dynamics of corticosteroid treatment classes

Leading brands of corticosteroid treatments

Corticosteroid treatments market analysis

Market dynamics

Key brands analysis

Corticosteroid treatment sales forecasts to 2011

Anti-infective treatments

Market analysis by drug class

Leading brands of anti-infective treatments

Market dynamics

Key brands analysis

Anti-infective treatment sales forecasts to 2011

Other dermatologic treatments

Leading brands of other dermatologic treatments

Key brands analysis

Other dermatologic treatment sales forecasts to 2011

Total Therapeutic market sales forecasts to 2011

Chapter 3 Pipeline analysis

Summary

Introduction

Key trends in R&D

New mechanism of action

Reformulations

Combination drugs

Biologics

The therapeutic area pipeline

Leading drugs in development

Profiles of key pipeline products

Phase II compounds

rambazole

Phase III compounds

Panaclar/BG-12

CNTO 1275 interleukin antagonist

Drugs in registration

Altabax (retapamulin)

Desonate (desonide)

Recently marketed drugs

Humira (adalimumab)

Oracea (doxycycline extended release sub anti-microbial dose)

Remicade (infliximab)

Taclonex (calcipotriene/betamethasone)

Ziana (clindamycin/tretinoin)

Pipeline forecasts

Factors affecting forecasts

Dermatology pipeline forecasts

Chapter 4 Competitive landscape

Summary

Introduction

Company market shares

Novartis

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline analysis

Strategic and growth analysis

Drivers of growth

Resistors of growth

GlaxoSmithKline

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline analysis

Strategic and growth analysis

Drivers of growth

Resistors of growth

Schering-Plough

Overview

Sales focus by drug class

Marketed Product Portfolio

R&D pipeline analysis

Strategic and growth analysis

Drivers of growth

Resistors of growth

Sanofi-Aventis

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline analysis

Strategic and growth analysis

Drivers of growth

Resistors of growth

Johnson & Johnson

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline analysis

Strategic and growth analysis

Drivers of growth

Resistors of growth

Bayer Schering Pharma

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline analysis

Strategic and growth analysis

Drivers of growth

Resistors of growth

Stiefel Labs

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline analysis

Strategic and growth analysis

Drivers of growth

Resistors of growth

Roche

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline analysis

Strategic and growth analysis

Drivers of growth

Resistors of growth

Nestle/L’Oreal

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline analysis

Strategic and growth analysis

Drivers of growth

Resistors of growth

Chapter 5 Appendix

IMS data

Index

List of Figures

Figure 1.1: Typical treatment patterns in the treatment of acne

Figure 1.2: Typical treatment patterns in the treatment of psoriasis

Figure 2.3: Global dermatology market share by geography, 2005

Figure 2.4: Sales of types of dermatology brands, 2004-5

Figure 2.5: Competitive dynamics of the global dermatology market by drug class, 2005

Figure 2.6: Competitive dynamics of the leading 10 brands in the global dermatology market,

2004-5

Figure 2.7: Competitive dynamics of subclasses in the acne treatments market, 2004-5

Figure 2.8: Competitive dynamics of the leading acne treatments in the global dermatology

market, 2004-5

Figure 2.9: Competitive dynamics of the leading oral acne treatments in the global dermatology

market, 2004-5

Figure 2.10: Competitive dynamics of the leading topical acne treatments in the global dermatology

market, 2004-5

Figure 2.11: Competitive dynamics of classes in the psoriasis treatments market, 2004-5

Figure 2.12: Competitive dynamics of the leading psoriasis treatments in the global dermatology

market, 2004-5

Figure 2.13: Competitive dynamics of classes in the corticosteroid treatments market, 2004-5

Figure 2.14: Competitive dynamics of the leading corticosteroid treatments in the global

dermatology market, 2004-5

Figure 2.15: Competitive dynamics of subclasses in the anti-infective treatments market, 2004-

Figure 2.16: Competitive dynamics of the leading anti-infective treatments in the global

dermatology market, 2004-5

Figure 2.17: Competitive dynamics of the leading other treatments in the global dermatology

market, 2004-5

Figure 3.18: Prevailing R&D approaches, 2005

Figure 3.19: The dermatology pipeline by indication and stage of development, 2006

Figure 3.20: Leading recently launched products and late-stage R&D in the dermatology market,

2005

Figure 4.21: Competitive dynamics of the leading players in the global dermatology market,

Figure 4.22: Novartis’ dermatology sales, 2005

Figure 4.23: GSK’s dermatology sales by drug class, 2005

Figure 4.24: Schering-Plough’s dermatology sales by drug class, 2005

Figure 4.25: Sanofi-Aventis’ dermatology sales by drug class, 2005

Figure 4.26: J&J’s dermatology sales by drug class, 2005

Figure 4.27: Schering AG’s dermatology sales by drug class, 2005

Figure 4.28: Stiefel Labs’ dermatology sales by drug class, 2005

Figure 4.29: Roche’s dermatology sales by drug class, 2005

Figure 4.30: L’Oreal’s dermatology sales by drug class, 2005

List of Tables

Table 1.1: Estimated prevalence of dermatological conditions in the seven major pharmaceutical

markets, 2005

Table 1.2: Estimated prevalence of clinical acne across seven major markets, 2005

Table 1.3: Forecast epidemiology of clinical acne across the seven major markets, 2005-11

Table 1.4: Estimated prevalence of psoriasis across seven major markets, 2005

Table 1.5: Forecast epidemiology of psoriasis across the seven major markets, 2005-11

Table 1.6: Estimated prevalence of infectious diseases (viral) of the skin across seven major

markets, 2005

Table 1.7: Estimated prevalence of infectious diseases (fungal) of the skin across seven major

markets, 2005

Table 1.8: Estimated prevalence of infectious diseases (bacterial) of the skin across seven major

markets, 2005